Tal Zaks's Israeli startup targets rare genetic diseases

Tal Zaks credit: Dani Machlis
Tal Zaks credit: Dani Machlis

The former Moderna CMO, who led development of the company's Covid vaccine, tells "Globes" about Averna Therapeutics, which through gene editing is developing groundbreaking drugs.

There are hardly any drug development companies in Israel today that are based on deep science and well-funded from the outset, but now a gene editing company called Averna Therapeutics (formerly Exsilio Therapeutics) is setting out after raising $82 million last summer and with one name that opens doors: Dr. Tal Zaks, who served as chief medical officer at Moderna, when it developed and launched its Covid vaccine.

Zaks was a familiar face in the biotech industry during the Covid pandemic, and due to the meteoric rise in Moderna's share price, he also became very wealthy. Following a signed agreement to sell shares as soon as they passed a certain price, there were times when he was becoming $1 million richer each week. The STAT website estimated he accumulated tens of millions of dollars in capital at Moderna.

He left Moderna in February 2021, and the share price continued to break many more records, but Zaks claimed at the time that the company was entering its commercial phase, while he was looking for projects with a greater scientific challenge, like Averna.

The early stage company is developing a new approach to gene editing to treat rare genetic diseases. It does this using mRNA, the technology underlying the Covid vaccines, so the fact that Zaks is leading Averna has sparked a lot of interest in the field. In the future, it has the potential to develop drugs for cancer and more common autoimmune diseases.

Most of the healthcare companies that have been established in Israel in recent years have been in the fields of medical devices, digital health, or artificial intelligence for drug development. These companies usually start with a small initial investment and must achieve a lot with very little until they prove themselves and gain momentum.

Averna is a different story. The company was founded by Roy Amariglio, formerly a researcher at the Weizmann Institute of Science and an executive at pharmaceutical company Bayer, and today an investor in the OrbiMed venture capital fund.

Zaks tells "Globes," "Roy identified a scientific opportunity that had not been exploited properly. He mobilized OrbiMed partner Erez Chimovits and together they located the founding team, one of them is Israeli - Erez Levanon.

Zaks met him in 2023. Since leaving Moderna, he had served in several positions including a director at Teva Pharmaceuticals and a partner at OrbiMed. "I was enthusiastic about the technology and thought this was a situation where you could raise significant capital and build a more established company," he says. "I joined the company as executive chairman and interim CEO, and we raised the Series A financing round."

The company was initially called Exsilio and is now being unveiled under the new name Averna, and also with a new CEO, Tom Barnes, former CEO of oRNA Therapeutics and today an investor in the MPM fund.

Investment from a rival company

"We are developing the last missing tool in the gene editing toolbox," Barnes tells Globes. "In recent years, drugs based on RNAi, a type of RNA that prevents gene expression, have been approved, and in 2023, a drug based on CRISPR was approved, a kind of genetic scissors that can cut and remove a piece of a gene, but they are limited in the amount of DNA they can put into a cell and there are concerns about safety issues.

"When we talk about introducing a new gene, it is usually done using a virus that carries the desired DNA and inserts it into the genome. But we have discovered in recent years that you need to bring a lot of genetic material with a large amount of virus into the cell to perform successful editing, and sometimes it is difficult for the body.

"Some of the gene editing in medicine is done outside the body today, for example CAR-T therapy for cancer, but this approach is only relevant for a small number of applications.

"The Covid vaccines basically showed that it is possible to bring genetic data to cells and make them produce a genetic sequence that is not in the genome, but temporarily. We want to do this with RNA that is permanently copied into the DNA. We have developed this ability over the last three years."

Barnes says that when the idea was presented to him, he was not sure that it would be applicable, but initial experiments conducted by the company convinced him that it was possible. "I was convinced that it was possible to work with this approach and scale it up, although we are not quite there yet."

The company is not yet disclosing which genetic diseases its technology will be used for, or exactly how it works, for fear of competition from companies trying to solve the same problem in different ways. The company has many competitors, but CRISPR Therapeutics, ostensibly a rival of Averna, is one of the investors in the company’s Series A round, evidence that it sees it as its potential next generation.

Zaks explains that the company’s product inserts the new DNA into areas of the cell that are considered protected spaces, so that the genes cannot replicate in unwanted places and damage the cell’s function. He also stresses that the company’s technology can perform gene therapy more than once with less fear of an immune response, which allows it to insert more genetic data.

"This type of gene editing should also allow for the treatment of diseases whose origin is not genetic or whose origin cannot be identified in one particular gene," says Saks. "As long as the problem can be corrected or helped, say, by producing more of a certain protein, and we know how to build a gene that produces that protein, then it is potentially possible to develop a drug."

Averna has 35 employees, most of them in Israel. The aim is to keep the research in Israel, and share development between Israel and the US. The money already raised is to move the company to the preclinical trial stage.

It's no small matter to do all this from Israel

Saks: "Right, and it hasn't been an easy year. I give a lot of credit to the team and their resilience, but I admit that the challenge was very difficult, on all fronts. Both personally for the employees who were affected by the war in various ways, also in terms of the company's communication with the team from abroad when there are no flights and it's difficult to meet. I'm optimistic and believe that things are going to get better, the biotech market itself is also getting better, and now Tom is with us."

Moderna, the company you left, has had a bit more difficulty in the last two years. They haven't yet managed to replicate the success of the Covid vaccines.

"Moderna is an amazing company, and they were pioneers and showed us the way too. Today I can't speak for them. I can't speak for Teva, where I'm a director, except to say that I'm so proud of them for the recovery they've made."

A market in its infancy

The field of gene editing has only begun to realize its potential in recent years, more than 20 years after the genome was decoded, and about a decade after the invention of the CRISPR-Cas9 technology that made gene editing accessible to laboratories around the world.

In 2017, the first technology for gene editing of cells outside the body and their return (CAR-T) was approved, and today this treatment market is worth billions of dollars annually. The FDA has also approved two gene-editing-based drugs for muscular dystrophy despite controversy over their effectiveness, and in 2023, CRISPR Therapeutics received approval for a CRISPR-based drug to treat the blood diseases beta thalassemia and sickle cell anemia. There are currently dozens of other products in clinical trials that use gene editing using different technologies.

Published by Globes, Israel business news - en.globes.co.il - on January 28, 2025.

© Copyright of Globes Publisher Itonut (1983) Ltd., 2025.

Tal Zaks credit: Dani Machlis
Tal Zaks credit: Dani Machlis
Ella Kenan  credit: Yossi Cohen A fighter of fake news about Israel

Ella Kenan saw online denial of October 7 happening straightaway. "I realized we had 24 hours, or we were doomed"

Liron Horshi credit: Jonathan Bloom Wiz's talent manager nurtures $1b workforce

Wiz's $32 billion sale to Google was rooted in the cloud security product if offers but could not have been achieved without the quality of its employees built by human resources chief Liron Horshi.

Yoav Shoham  credit: Eyal Izhar Yoav Shoham: AI isn't too smart, it's too dumb

AI21 Labs founder and CEO Prof. Yoav Shoham talks to "Globes" about dubious doomsday predictions, what should really concern us, and what could make Israel a global AI leader.

Insightec COO and general manager Eyal Zadicario credit: Ness Productions After 25 years of losses Insightec focuses on profit

Insightec COO and general manager Eyal Zadicario tells "Globes" about himself and the Israeli ultrasound company's long battle to change the medical world.

Amit Shaked credit: Tomer Lesher Driven to succeed but balancing ambition with wellbeing

At just 14, cybersecurity company Rubrik VP Amit Shaked began a B.Sc. in Computer Science and Math and mapped out his entire future, which included IDF service in the 8200 unit, and an inevitable huge startup exit.

Dr. Ola Gutzeit  credit: Ketty Hakim The doctor breaking new ground in fertility

"We know nothing about the female reproductive system," says Dr. Ola Gutzeit of Rambam Hospital. She seeks to change that, and hence change IVF for the better.

Google CEO Sundar Pichai  crediit: Shutterstock Why Google is paying so much for Wiz

Lagging its competitors in cloud and AI, and facing challenges to its core advertising business, Google could be looking to spend its way out of trouble.

Prof. Douglas Irwin  credit: Inbal Marmari "We will all be poorer"

Prof. Douglas Irwin, an expert on international trade, talks to "Globes" about the impact of President Trump's tariffs policy, and what Israel can do about it.

Rooftop solar panels credit: Shutterstock Does it pay for homes to install rooftop solar panels?

As the Israeli government steps up efforts to encourage homeowners to produce their own electricity from rooftop panels, "Globes" investigates the advantages and pitfalls.

UnitedHealth founder Richard Burke credit: Ken Easley UnitedHealth founder: US health system is broken

In an exclusive interview Richard Burke talks about the murder of the company's CEO, Donald Trump, his love for Israel, and investment in Israeli startup Korro AI.

Left to right: Karin Goldberg, Einav Laser, Dr. Arseniy Lobov, Dr. Paola Antonello, Dr. Merav Shmueli, and Prof. Yifat Merbl (center in black)  credit: Weizmann Institute Israeli scientists' discovery could lead to new antibiotics

Prof. Yifat Merbl of the Weizmann Institute and her team have found a natural source of anti-microbial substances in the "garbage can" of human cells.

Peter Kash credit: personal photograph Peter Kash confident about cancer cure breakthrough

In Israel for IATI's MIXiii International Life Science and Health-Tech week, the US investor talks about his life science portfolio and the opportunities Israel must seize.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018